| Identification | Back Directory | [Name]
6-Quinolinecarboxamide, N-[5-[[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]amino]-2-methylphenyl]-2-methyl- | [CAS]
1693731-14-4 | [Synonyms]
N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-methylphenyl)-2-methylquinoline-6-carboxamide
6-Quinolinecarboxamide, N-[5-[[(2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl]amino]-2-methylphenyl]-2-methyl- | [Molecular Formula]
C27H23N3O4 | [MOL File]
1693731-14-4.mol | [Molecular Weight]
453.49 |
| Chemical Properties | Back Directory | [Boiling point ]
535.5±50.0 °C(Predicted) | [density ]
1.349±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 41.67 mg/mL (91.89 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
12.49±0.70(Predicted) | [color ]
Off-white to light brown |
| Hazard Information | Back Directory | [Uses]
CCT245232 is a potent inhibitor of heat shock factor 1 (HSF1). HSF1 is the master regulator of the heat shock response, in which multiple genes are induced in response to temperature increase and other stresses. CCT245232 has the potential for the research of proliferative diseases, such as cancer (extracted from patent WO2015049535A1)[1]. | [Biological Activity]
CCT245232 is a potent inhibitor of heat shock factor 1 (HSF1). HSF1 is the master regulator of the heat shock response, in which multiple genes are induced in response to temperature increase and other stresses. CCT245232 has the potential for the research of proliferative diseases, such as cancer (extracted from patent WO2015049535A1)[1]. | [References]
[1]. Keith Jones, et al. Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1. Patent WO2015049535A1. |
|
|